Fosun Pharma’s MSCI ESG Rating Upgrades to A

SHANGHAI, October 13, 2022 /PRNewswire/ — Morgan Stanley Capital International (“MSCI”), the world’s leading index company, recently announced the results of its latest annual environmental, social and governance (“ESG”) rating. In recognition of its outstanding performance in ESG, MSCI has raised the ESG rating of Fosun Pharma (stock code: 600196.SH, 02196.HK) from BBB to Aranking at the highest level China. Fosun Pharma’s MSCI ESG rating was upgraded from BB in 2020 to BBB in 2021. The continued upgrade to A this year demonstrates the strong recognition of Fosun Pharma’s ESG management by the capital market and shows the value of long-term investment from Fosun Pharma.

The MSCI ESG rating is one of the best ESG rating systems recognized by investment institutions around the world. The latest rating update is based on Fosun Pharma’s outstanding performance in environmental, social and corporate governance.

Regarding environmental protection, Fosun Pharma has established an EHS committee, built a perfect EHS management system, and continued to promote ISO14001 certification for its member companies. In addition, based on the complete achievement of the last five-year EHS management strategic goal, the second five-year strategic goal (2021-2026) has been set to continue promoting the reduction of waste gas, wastewater and disposal. waste, reduce energy and water consumption, and greenhouse gas emissions.

With regard to social responsibility, Fosun Pharma is committed to addressing unmet clinical needs, continuously improving product accessibility and affordability, and bringing benefits to more patients. By the end of 2021, Artesun® had been used to treat more than 48 million patients with severe malaria worldwide. To date, 175 million children in African countries with high malaria transmission have benefited from the “Seasonal Malaria Chemoprevention Programme”, for which SPAQ-CO® Disp is used as the basic drug, effectively reducing malaria morbidity in children under five years of age Africa. During the pandemic, Fosun Pharma has been actively working in various aspects such as drug research and development, donating supplies, etc., and striving to ensure the supply of test kits, emergency drugs , medical equipment, etc. product quality, Fosun Pharma has implemented a product lifecycle quality management system, which strictly controls the quality of each step, from raw material sourcing and production to product storage. . In terms of talent training, Fosun Pharma has established diversified recruitment channels and continued to attract talent. It also established a corporate university – Fosun University of Healthcare Management, to provide employees with sufficient support for learning and personal development.

Regarding corporate governance, Fosun Pharma has set up an ESG committee to the board of directors to oversee the group’s ESG issues. The ESG Committee has set up an ESG working group to fully implement the group’s ESG strategy, thus integrating ESG management into day-to-day operations. The company has a comprehensive anti-corruption system, promoted by an independent integrity inspection service, and ensures compliance of internal and external stakeholders of the company through training, audits and other methods. In addition, the company also continues to maintain professional, brand, digital and compliant marketing control.

Founded in 1994, Fosun Pharma is an innovation-driven global pharmaceutical and healthcare group with deep roots in China. It has always actively promoted ESG management and disclosure, continuing to improve its ESG system, aiming for long-term sustainable development.

Fosun Pharma has published a corporate social responsibility report for 14 consecutive years and disclosed the ESG report in the annual report for two consecutive years, continuously disclosing the company’s ESG performance to stakeholders. In terms of awards and ratings, Fosun Pharma received WIND ESG A rating and was listed in China Top 500 ESG companies. In August 2022, Fortune China’s first ESG impact list selected 40 companies with Fosun Pharma at the top of the list. Fosun Pharma’s 2021 Corporate Social Responsibility Report received a five-star rating (Excellence) and won the Outstanding Company Award for Corporate Social Responsibility and Technology Innovation in “2021 China Benefit Corporation”.

Going forward, Fosun Pharma will constantly improve its ESG management system and promote ESG governance. By taking concrete steps to fulfill its social responsibility, Fosun Pharma will continue to improve the satisfaction of investors and other stakeholders.

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is an innovation-driven global pharmaceutical and healthcare group with deep roots in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnostics and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas of distribution and retailing of pharmaceutical products.

Fosun Pharma is patient-centered and focused on clinical needs. The company enriches its pipeline of innovative products through diversified and multi-level cooperation models such as independent research and development, cooperative development, licensing and deep incubation. Fosun Pharma has formed technology platforms for innovative small molecule drugs, antibodies and cell therapy, focusing on key disease areas including oncology and immunomodulation, metabolism and digestive system, as well as than the central nervous system. Fosun Pharma also vigorously explores advanced technologies, such as RNA, gene therapy, ADC and PROTAC, to enhance its innovation capabilities.

Guided by the 4IN (Innovation, Internationalization, Intelligentization and Integration) strategy, Fosun Pharma will maintain the development model of “transformation of innovation, integrated operation and steady growth”, with the mission of creating value for shareholders by strengthening its independent R&D and cooperation and the enrichment of its product pipelines, as well as the promotion of global networks and the improvement of operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a premier enterprise in the global medical and healthcare industry. market.

SOURCE Fosun Pharma

Back To Top